To test whether LEC-derived chemokines play a role in MDSC recruitment, we collected tumors, and tumor-draining and distant lymph nodes from mice that received vehicle or CXCR2-antagonist SB225002 treatments, and quantified the amount of CD11b+/Gr-1+ MDSCs in those tissues by flow cytometry. This evidence concerns the gene CXCR2 and neoplasm.